Table 3.

Odds of overweight or obese among offspring of women using a pharmacologic sex hormone - by months of first use

				Overweight or obese (≥85th percentile)			Obese (≥95th percentile)
Exposure		Exposed n	Exposed cases n	Crude OR (95% CI)	Adjusted* OR (95% CI)	Exposed cases n	Crude OR (95% CI)	Adjusted* OR (95% CI)
OC months of first use**
	None	34,223	4,920	referent	referent	1,731	referent	referent
	1–2	159	27	1.3 (0.8, 1.9)	1.4 (0.9, 2.1)	12	1.6 (0.9, 2.8)	2.0 (1.1, 3.7)
	2–3	52	10	1.4 (0.7, 2.8)	1.6 (0.8, 3.1)	2	0.7 (0.2, 3.1)	0.9 (0.2, 4.1)
	3–4	37	7	1.3 (0.6, 3.1)	1.3 (0.5, 3.2)	0	--†	--†
DES months of first use**
	None	34,288	4,929	referent	referent	1,730	referent	referent
	1–2	51	6	0.8 (0.4, 1.9)	0.5 (0.2, 1.3)	3	1.2 (0.4, 3.7)	0.8 (0.3, 2.5)
	2–3	69	12	1.2 (0.6, 2.3)	0.7 (0.4, 1.4)	7	2.2 (1.0, 4.7)	1.4 (0.6, 3.0)
	3–4	52	16	2.4 (1.3, 4.3)	1.7 (0.9, 3.2)	9	3.8 (1.8, 7.8)	2.8 (1.3, 6.3)
	4–5	32	9	2.1 (1.0, 4.6)	2.0 (0.9, 3.2)	4	2.5 (0.9, 7.6)	2.6 (0.8, 8.6)
	5–6	22	2	0.5 (0.1, 2.7)	0.6 (0.1, 2.6)	0	--†	--†
	6–7	9	1	0.6 (0.1, 7.1)	0.6 (0.1, 5.9)	1	2.4 (0.3, 18.4)	2.5 (0.3, 20.2)
	7–8	6	1	1.2 (0.1, 10.1)	1.2 (0.1, 12.3)	1	3.7 (0.4, 31.9)	4.5 (0.4, 56.6)
	8–9	4	0	--†	--†	0	--†	--†
by month of start‡		--	--	1.1 (0.9, 1.2)	1.0 (0.9, 1.1)	--	1.2 (1.0, 1.4)	1.2 (1.0, 1.4)

^*adjusted for maternal smoking, education, parity, race, pre-pregnancy BMI, maternal age, and study center

^**months of first documented use in pregnancy

^†not estimable

^‡represents OR for one unit increase in month for month of start of use